BjornevikKCorteseMHealyBC, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science2022; 375(6578): 296–301.
2.
WandingerKJabsWSiekhausA, et al. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology2000; 55(2): 178–184.
3.
SoldanSSSuCMonacoMC, et al. Multiple sclerosis patient-derived spontaneous B cells have distinct EBV and host gene expression profiles in active disease. Nat Microbiol2024; 9(6): 1540–1554.
4.
MunzC.Altered EBV specific immune control in multiple sclerosis. J Neuroimmunol2024; 390: 578343.
5.
GiovannoniG.Targeting Epstein-Barr virus in multiple sclerosis: When and how?Curr Opin Neurol2024; 37(3): 228–236.
6.
YuanLZhongLKrummenacherC, et al. Epstein-Barr virus-mediated immune evasion in tumor promotion. Trends Immunol2025; 46(5): 386–402.
7.
DaiYZhangBYangL, et al. Recent progress in the vaccine development against Epstein-Barr virus. Viruses2025; 17(7): 936.
8.
SmithCKhannaR.Adoptive T-cell therapy targeting Epstein-Barr virus as a treatment for multiple sclerosis. Clin Transl Immunology2023; 12(3): e1444.
9.
LanzTVBrewerRCHoPP, et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature2022; 603(7900): 321–327.
10.
van de Waterweg BerendsABrouxBMachielsB, et al. The EBV-MS connection: The enigma remains. Front Immunol2024; 15: 1466339.
